Semaphorins in cardiovascular medicine

Trends in Molecular Medicine

Volumn 20, Issue 10, 2014, Pages 589-598

  Corà, Davide ^a,b   Astanina, Elena ^a,b   Giraudo, Enrico ^b,c   Bussolino, Federico ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenesis; Cardiac diseases; Endothelial cells; Plexins; Vascular diseases

Indexed keywords

SEMAPHORIN; SEMAPHORIN 3A; SEMAPHORIN 3C; SEMAPHORIN 3D; SEMAPHORIN 3E; SEMAPHORIN 3F; SEMAPHORIN 4A; UNCLASSIFIED DRUG; SEMA3D PROTEIN, HUMAN;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL MIGRATION; ELECTRIC CONDUCTIVITY; EMBRYONIC ANGIOGENESIS; HEART DEVELOPMENT; HEART INNERVATION; HEART RATE; ISCHEMIA; LUNG VEIN DRAINAGE ANOMALY; LYMPHANGIOGENESIS; MISSENSE MUTATION; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR BIOLOGY; ANIMAL; EMBRYOLOGY; GENETICS; HEART; HUMAN; INNERVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HEART; HUMANS; ISCHEMIA; LYMPHANGIOGENESIS; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PHYSIOLOGIC; SEMAPHORINS;

EID: 84908142178     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.07.005     Document Type: Review

References (82)

1. Kolodkin A.L., et al. Fasciclin IV: sequence, expression, and function during growth cone guidance in the grasshopper embryo. Neuron 1992, 9:831-845.
2. Siebold C., Jones E.Y. Structural insights into semaphorins and their receptors. Semin. Cell Dev. Biol. 2013, 24:139-145.
3. Kumanogoh A., Kikutani H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat. Rev. Immunol. 2013, 13:802-814.
4. Goel H.L., et al. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J. Cell Sci. 2012, 125:497-506.
5. Valdembri D., et al. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol. 2009, 7:e25.
6. Hota P.K., Buck M. Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell. Mol. Life Sci. 2012, 69:3765-3805.
7. Behar O., et al. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 1996, 383:525-528.
8. Soker S., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
9. Vander Kooi C.W., et al. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6152-6157.
10. Kawasaki T., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999, 126:4895-4902.
11. Zhou J., et al. Endothelial neuropilin disruption in mice causes DiGeorge syndrome-like malformations via mechanisms distinct to those caused by loss of Tbx1. PLoS ONE 2012, 7:e32429.
12. Stalmans I., et al. VEGF: a modifier of the del22q11 (DiGeorge) syndrome?. Nat. Med. 2003, 9:173-182.
13. Feiner L., et al. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development 2001, 128:3061-3070.
14. Keyte A., Hutson M.R. The neural crest in cardiac congenital anomalies. Differentiation 2012, 84:25-40.
15. Toyofuku T., et al. Repulsive and attractive semaphorins cooperate to direct the navigation of cardiac neural crest cells. Dev. Biol. 2008, 321:251-262.
16. Lepore J.J., et al. GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis. J. Clin. Invest. 2006, 116:929-939.
17. Worzfeld T., et al. Genetic dissection of plexin signaling in vivo. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:2194-2199.
18. Kodo K., et al. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13933-13938.
19. Ta-Shma A., et al. Isolated truncus arteriosus associated with a mutation in the plexin-D1 gene. Am. J. Med. Genet. A 2013, 161A:3115-3120.
20. Silversides C.K., et al. Rare copy number variations in adults with tetralogy of Fallot implicate novel risk gene pathways. PLoS Genet. 2012, 8:e1002843.
21. Li W., et al. Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1738-1743.
22. Gitler A.D., et al. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev. Cell 2004, 7:107-116.
23. Zhang Y., et al. Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. Dev. Biol. 2009, 325:82-93.
24. Schulz Y., et al. CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance. Hum. Genet. 2014, 133:997-1009.
25. Degenhardt K., et al. Semaphorin 3d signaling defects are associated with anomalous pulmonary venous connections. Nat. Med. 2013, 19:760-765.
26. Sakurai A., et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol. Cell. Biol. 2010, 30:3086-3098.
27. Gu C., et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268.
28. Meadows S.M., et al. Integration of repulsive guidance cues generates avascular zones that shape mammalian blood vessels. Circ. Res. 2012, 110:34-46.
29. Zygmunt T., et al. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev. Cell 2011, 21:301-314.
30. Meadows S.M., et al. Resolution of defective dorsal aortae patterning in Sema3E-deficient mice occurs via angiogenic remodeling. Dev. Dyn. 2013, 242:580-590.
31. Pérez-Pomares J.M., de la Pompa J.L. Signaling during epicardium and coronary vessel development. Circ. Res. 2011, 109:1429-1442.
32. Katz T.C., et al. Distinct compartments of the proepicardial organ give rise to coronary vascular endothelial cells. Dev. Cell 2012, 22:639-650.
33. Red-Horse K., et al. Coronary arteries form by developmental reprogramming of venous cells. Nature 2010, 464:549-553.
34. Ieda M., et al. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat. Med. 2007, 13:604-612.
35. Maden C.H., et al. NRP1 and NRP2 cooperate to regulate gangliogenesis, axon guidance and target innervation in the sympathetic nervous system. Dev. Biol. 2012, 369:277-285.
36. Chen R., et al. Overexpression of sema3a in myocardial infarction border zone decreases vulnerability of ventricular tachycardia postmyocardial infarction in rats. J. Cell. Mol. Med. 2013, 17:608-616.
37. Nakano Y., et al. A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillation. PLoS Genet. 2013, 9:e1003364.
38. Boczek N.J., et al. Characterization of SEMA3A-encoded semaphorin as a naturally occurring Kv4.3 protein inhibitor and its contribution to Brugada syndrome. Circ. Res. 2014, 115:460-469.
39. James J.M., Mukouyama Y.S. Neuronal action on the developing blood vessel pattern. Semin. Cell Dev. Biol. 2011, 22:1019-1027.
40. Torres-Vazquez J., et al. Semaphorin-plexin signaling guides patterning of the developing vasculature. Dev. Cell 2004, 7:117-123.
41. Bussolino F., et al. Class 3 semaphorin in angiogenesis and lymphangiogenesis. Chem. Immunol. Allergy 2014, 99:71-88.
42. Oh W.J., Gu C. The role and mechanism-of-action of Sema3E and Plexin-D1 in vascular and neural development. Semin. Cell Dev. Biol. 2013, 24:156-162.
43. Reidy K.J., et al. Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. Development 2009, 136:3979-3989.
44. Oh W.J., Gu C. Establishment of neurovascular congruency in the mouse whisker system by an independent patterning mechanism. Neuron 2013, 80:458-469.
45. Kim J., et al. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev. 2011, 25:1399-1411.
46. Bonneau C., et al. Lymphatic and nerve distribution throughout the parametrium. Gynecol. Oncol. 2013, 131:708-713.
47. D'Andrea V., et al. Cholinergic innervation of human mesenteric lymphatic vessels. Folia Morphol. (Warsz) 2013, 72:322-327.
48. Bouvrée K., et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ. Res. 2012, 111:437-445.
49. Jurisic G., et al. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ. Res. 2012, 111:426-436.
50. Norrmén C., et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J. Cell Biol. 2009, 185:439-457.
51. Fang J., et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 2000, 67:1382-1388.
52. Yuan L., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002, 129:4797-4906.
53. Caunt M., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
54. Bielenberg D.R., et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Invest. 2004, 114:1260-1271.
55. Takamatsu H., et al. Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat. Immunol. 2010, 11:594-600.
56. Neufeld G., Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 2008, 8:632-645.
57. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell 2012, 22:145-152.
58. Serini G., et al. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. J. Intern. Med. 2013, 273:138-155.
59. Meda C., et al. Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in macrophages. J. Immunol. 2012, 188:4081-4092.
60. Moriya J., et al. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis. Circ. Res. 2010, 106:391-398.
61. Zacchigna S., et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J. Clin. Invest. 2008, 118:2062-2075.
62. Jiang S.X., et al. Neuropilin 1 directly interacts with Fer kinase to mediate semaphorin 3A-induced death of cortical neurons. J. Biol. Chem. 2010, 285:9908-9918.
63. Pekcec A., et al. Following experimental stroke, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling. FASEB J. 2013, 27:437-445.
64. Fukushima Y., et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J. Clin. Invest. 2011, 121:1974-1985.
65. Joyal J.S., et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 2011, 117:6024-6035.
66. Rivera J.C., et al. Microglia and interleukin-1β in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1881-1891.
67. Cerani A., et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013, 18:505-518.
68. van Gils J.M., et al. Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler. Thromb. Vasc. Biol. 2013, 33:911-919.
69. Wanschel A., et al. Neuroimmune guidance cue semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 2013, 33:886-893.
70. Yukawa K., et al. Deletion of Sema4D gene reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Int. J. Mol. Med. 2010, 26:39-44.
71. Luque M.C., et al. Phage display identification of CD100 in human atherosclerotic plaque macrophages and foam cells. PLoS ONE 2013, 8:e75772.
72. Reidy K.J., et al. Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction. Am. J. Pathol. 2013, 183:1156-1168.
73. Maione F., et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 2009, 119:3356-3372.
74. Maione F., et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 2012, 122:1832-1848.
75. Casazza A., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24:695-709.
76. Wong H.K., et al. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 2012, 14:84-94.
77. Sadanandam A., et al. Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. Br. J. Cancer 2012, 107:501-507.
78. Segarra M., et al. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 2012, 120:4104-4115.
79. Toyofuku T., et al. Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. Nat. Cell Biol. 2004, 6:1204-1211.
80. Kessler O., et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 2004, 64:1008-1015.
81. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 2013, 31:2205-2218.
82. Carrer A., et al. Neuropilin 1 identifes a subset of GR-1 monocytes that induce tumor vessel normalization and inhibit tumor growth. Cancer Res. 2012, 75:6371-6381.